B7-H4 Expression is Associated with Cancer Progression and Predicts Patient Survival in Human Thyroid Cancer

Jian Zhu, Bing-Feng Chu, Yi-Peng Yang, Sheng-Lai Zhang*, Ming Zhuang, Wen-Jie Lu, Ying-Bin Liu

Abstract

Objective: This study aimed to investigate the expression of B7-H4 in human thyroid cancer and determine any association with patient clinicopathological parameters and survival. Methods: B7-H4 expression in 64 clinical thyroid cancer specimens was assessed with immunohistochemistry. Moreover, B7-H4 mRNA expression in 10 fresh resected specimens were evaluated by the reverse transcription-polymerase chain reaction (RT-PCR). Immunohistochemical staining of CD3 was performed to assess the number of tumor infiltrating T lymphocytes (TILs) in thyroid cancers. Results: Positive B7-H4 immunohistochemical staining was observed in 61 out of 64 (95.3%) specimens of thyroid cancer tissues. Significantly more B7-H4 mRNA copies were found in thyroid cancer tissue than that adjacent normal tissue. Moreover, B7-H4 expression in human thyroid cancer tissues was significantly correlated with patient TNM stages and extrathyroidal extension (P<0.05), being inversely correlated with the number of TILs (P<0.05). The overall survival rate of the patients with higher B7-H4 expression was significantly worse than that of the patients with lower B7-H4 expression. Conclusions: This present study suggests that high B7-H4 expression is associated with cancer progression, reduced tumor immunosurveillance and worse patient outcomes in human thyroid cancer.

Keywords: Thyroid cancer - B7-H4 - progression - prognosis - tumor infiltrating lymphocytes
Materials and Methods

Patient population

Formalin-fix, paraffin-embedded tumor tissue blocks were collected retrospectively from the Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine. All of the 64 thyroid cancer patients underwent surgical resection between December 2006 and August 2008 in Xinhua hospital. None of the patients received chemotherapy or radiotherapy before surgery. The pathologic reports were reviewed, and the tumor–node–metastasis (TNM) stages were assigned according to the American Joint Committee on Cancer staging system. Patients' clinical parameters are shown in Table 1, and patients' survival intervals are dated toward the end of December 2012. In addition, 8 normal tissues from the non-malignant portion of thyroid were resected from surgery and used as controls. Ethical approval for this study was granted by the ethics committee of Xinhua hospital and informed consents were obtained.

Immunohistochemical staining

B7-H4 expression was analyzed using human thyroid cancer and normal tissue. Standard immunohistochemical procedures were carried out using VECTASTAIN Elite ABC system (Vector Laboratories, USA), according to the manufacturer’s protocol. Anti-B7-H4 monoclonal antibody (Abcam, USA) was used as a primary antibody. Similar tissue sections were immunostained with normal IgG were used as negative controls. In the immunohistochemical procedure for CD3, anti-human CD3 antibody (DAKO, USA) diluted 1:100 in PBS was used. The specimens were examined and scored using a two-headed microscope. Staining intensity (0, no staining; 1, weak staining; 2, moderate staining; and 3, intense staining) and the proportion of stained cells (0, no staining; 1, <10% staining; 2, between 11% and 33%; 3, between 34% and 66%; and 4, >67%) were semi-quantitatively determined. The intensity and percentage of positive cell scores were multiplied (0-12). All slides were scored by two observers blinded to the pathology and clinical features. There are good concordances between two observers. In cases where score difference was equal to or exceeding 2, the slides were re-examined and a consensus was reached by the observers. Mean score for duplicate cores from each individual was calculated.

Quantitative RT-PCR

Fresh tumor specimens were homogenized in FastPrep (Qbiogene, USA). Quantitative real-time PCR (qRT-PCR) analysis was carried out to detect the expression of B7-H4 in 10 human thyroid cancer tissues and corresponding adjacent normal tissues. Total RNA extraction from thyroid cancer tissue was performed with Trizol Reagent (Invitrogen). Then, 2 μg of total RNA was reverse-transcribed with Taqman (TakaRa PrimeScript™ RT Reagent Kit, Japan). The primers below were used to amplify B7-H4 and GAPDH. B7-H4: (Forward), 5’-GGGTGTGAACCATGAGAAGT-3’; (Reverse), 5’-GACTGTGGTCATGAGTCT-3’. Each reaction had a total volume of 25 μl, with reagents from the TaKaRa Ex Taq® kit. Thermocycling conditions included 40 cycles of denaturing at 94°C for 30 s, annealing at 55°C for 15 s and extension at 72°C for 60 s. Data from the array were normalized to GAPDH.

Statistical analysis

All statistics were performed with the GraphPad Prism version 5.0 for Windows (GraphPad Software, USA). The χ² test was used to assess the statistical significance of differences between the various tissue specimens. Correlation between variables was evaluated by Spearman’s rank correlation coefficients. Survival analysis was carried out using the Kaplan-Meier method and log-rank test. Differences were considered to be statistically significant at *P*<0.05.

Results

B7-H4 expression in human thyroid cancer tissues

The B7-H4 expression in 64 tissue specimens obtained from patients with thyroid cancer was assessed by immunohistochemical staining. Interobserver agreement in the assessment of immunohistochemical findings was excellent. Positive B7-H4 immunohistochemical staining was predominantly observed on the membrane and in cytoplasm of thyroid cancer cells (Figure 1), while weak staining was found in normal thyroid tissues. 61 out of 64 (95.3%) specimens of thyroid cancer tissues showed positive B7-H4 staining. Therefore, higher B7-H4 expression was identified in 46 (71.9%) of 64 thyroid cancer specimens. In this study, B7-H4 expression in 20 fresh tumor specimens from thyroid cancer patients was also assessed with the RT-PCR assay. In clinical thyroid tissues, B7-H4 mRNA expression was confirmed in all of tumor specimens and higher B7-H4 mRNA expression was found in tumor tissues than that in adjacent normal tissues (*P*<0.01) (Figure 2).

Figure 1. Representative Immunohistochemical Staining of B7-H4 Expression in Thyroid Cancer Tissues. Tumor cells with negative (A), weak (B), moderate (C), and strong (D) expression of B7-H4. Immunohistochemistry showed that positive B7-H4 immunochemical staining was predominantly observed on the membrane and in cytoplasm of tumor cells. Original magnification ×400.
The level of B7-H4 protein was positively correlated with metastasis (P < 0.05), whereas it is not correlated with patient's age, gender, tumor size, or TNM stage (P > 0.05). Our studies support the utility of B7-H4 as a novel biomarker for the discrimination of advanced clinicopathological parameters and supported that B7-H4 was involved in the progression of human thyroid cancer.

Correlation between tumor cell B7-H4 expression and densities of TILs

To investigate the relationship between B7-H4 expression and tumor immune surveillance, the number of tumor infiltrating T lymphocytes was assessed by CD3 immunohistochemical staining. TILs stained by CD3 antigen were diffusely identified in tumor foci and stroma (Figure 3A). The number of TILs was significantly lower in thyroid cancer patients with high B7-H4 expression (66.4 ± 36.2) than those in patients with low B7-H4 expression (101.7 ± 54.7) (P < 0.01) (Figure 3B). Consequently, the B7-H4 expression status of thyroid cancer cells was inversely correlated with the number of tumor infiltrating T lymphocytes (P < 0.01).

High B7-H4 expression associated with poor prognosis in human thyroid cancer

We then evaluated the association between B7-H4 expression and survival following radical cystectomy in thyroid cancer patients. Our data showed that higher expression of B7-H4 is associated with a poor outcome following radical cystectomy (Figure 4). The survival rates were significantly lower in patients with high B7-H4 expression than in those with low B7-H4 expression (P < 0.05). Our studies support the utility of B7-H4 as...

Table 1. B7-H4 Expression and Correlation with Clinical Parameters in Human Thyroid Cancer

<table>
<thead>
<tr>
<th>Clinical parameters</th>
<th>Cases</th>
<th>B7-H4 expression</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td>Group high&lt;sup&gt;a&lt;/sup&gt;</td>
<td>Group low&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Male</td>
<td>25</td>
<td>17 (68%)</td>
<td>8 (32%)</td>
</tr>
<tr>
<td>Female</td>
<td>39</td>
<td>29 (74%)</td>
<td>10 (26%)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;55</td>
<td>24</td>
<td>19 (79%)</td>
<td>5 (21%)</td>
</tr>
<tr>
<td>≥55</td>
<td>40</td>
<td>27 (68%)</td>
<td>13 (32%)</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1</td>
<td>19</td>
<td>12 (63%)</td>
<td>7 (37%)</td>
</tr>
<tr>
<td>≥1</td>
<td>45</td>
<td>34 (76%)</td>
<td>11 (24%)</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>30</td>
<td>17 (57%)</td>
<td>13 (43%)</td>
</tr>
<tr>
<td>II, III, IV</td>
<td>34</td>
<td>29 (85%)</td>
<td>5 (15%)</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>22</td>
<td>19 (86%)</td>
<td>3 (14%)</td>
</tr>
<tr>
<td>No</td>
<td>42</td>
<td>27 (64%)</td>
<td>15 (36%)</td>
</tr>
<tr>
<td>Extrapertithelial extension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>16</td>
<td>15 (94%)</td>
<td>1 (12%)</td>
</tr>
<tr>
<td>No</td>
<td>48</td>
<td>31 (67%)</td>
<td>17 (33%)</td>
</tr>
</tbody>
</table>

<sup>a</sup>B7-H4 staining score >6; <sup>b</sup>B7-H4 staining score ≤ 6

Correlation between B7-H4 expression and patient’s clinicopathological features

To further investigate the clinical relevance of B7-H4 protein levels in the thyroid cancer tissues, we categorized 64 patients into two major subgroups according to the intensity of B7-H4 immunohistochemical staining, i.e., the lower B7-H4 expression group (score ≤ 6, 18 cases), and the higher B7-H4 expression group (score > 6, 46 cases). The correlation between tumor cell B7-H4 expression and patients’ clinicopathologic parameters was shown in Table 1. It demonstrated that B7-H4 expression in human thyroid cancer tissues was significantly correlated with patient’s TNM stage (P < 0.05) and extrapertithelial extension (P < 0.05), whereas it is not correlated with patient’s age, gender, tumor sizes, and lymph node metastasis. It is worth mentioning that there was a trend toward a positive correlation between B7-H4 expression and lymph node metastasis (P = 0.08). Thus, our data demonstrated that the level of B7-H4 protein was positively correlated with...

Figure 2. Higher B7-H4 mRNA Expression in Clinical Thyroid Cancer Tissues. Quantification of RT-qPCR for B7-H4 mRNA expression in 10 matched human tissues was conducted using paired t test and bars correspond to mean ± SD (*P < 0.05). The relative B7-H4 mRNA expression was standardized to GAPDH.

Figure 3. Correlation Between B7-H4 Expression Status and the Number of Tumor Infiltrating T Lymphocytes in Thyroid Cancer. (A) Representative CD3 immunohistochemical staining for the assessment of tumor infiltrating T lymphocytes in thyroid cancer foci. Tumor infiltrating T lymphocytes were diffusely identified in tumor foci. Original magnification x200. (B) The B7-H4 expression status was inversely correlated with the number of tumor infiltrating T lymphocytes (P < 0.01). Horizontal bars indicate the mean number of tumor infiltrating T lymphocytes.

Figure 4. Kaplan-Meier Survival Curves for Thyroid Cancer Patients Based on B7-H4 Expression. Patients with high B7-H4 expression had a significantly poorer prognosis than those with low B7-H4 expression (P < 0.05).
B7-H4 is a member of the B7 gene family, which has been implicated in negatively regulating T-cell-mediated immunity. Here, we demonstrated that B7-H4 protein was overexpressed in human thyroid cancer tissues but weakly expressed in normal tissues. We also clarified the clinical significance of B7-H4 expression in thyroid cancer by investigating relationships between B7-H4 protein expression and clinicopathological factors including prognosis. We demonstrated that higher B7-H4 expression was positively correlated with advanced TNM stage and poor patient outcome, implicating its role in thyroid cancer progression. To our knowledge, this study is the first to assess B7-H4 expression and to explore its clinical significance in thyroid cancer. We believe that, with further investigation, B7-H4 could become a clinical prognostic marker and a target for immunotherapeutic treatment of human thyroid cancer.

The costimulatory B7 family members are cell-surface protein ligands, binding to receptors on lymphocytes to regulate immune responses (Flies et al., 2007). They not only provide positive signals to stimulate T-cell activation, but also regulate negative signals to inhibit T-cell responses. Inhibitory B7 molecules have been demonstrated to be upregulated in different tumors, which may contribute to tumor immune evasion (Chen, 2004). B7-H4, a member of the B7 family, has been identified as a negative regulatory molecule on the cell membrane, which inhibits the proliferation and cytokine production of CD4+ T and CD8+ T cells (Prasad et al., 2003; Sica et al., 2003). In the tumor microenvironment, B7-H4 binds to an unknown receptor on the T cell surface, inhibiting tumor-specific T cell activation and proliferation. Accumulated evidences has been shown that increased B7-H4 expression is involved in shaping the tumor microenvironment, and aberrant B7-H4 expression is associated with various clinicopathological features in many human malignancies (Zheng et al., 2012). In gastric cancer, B7-H4 significantly correlated with depth of tumor invasion, lymph node metastasis, and overall stage in gastric cancer (Arigami et al., 2010). B7-H4 expression was significantly higher in invasive breast cancer cells and increased B7-H4 expression was associated with negative progesterone receptor status in breast cancer patients (Tringler et al., 2005). Furthermore, the measurement of B7-H4 expression is expected to become a useful tool for the prediction of chemotherapeutic response and prognosis in ovarian cancer patients and gastric cancer patients (Oikonomopoulou et al., 2008; Arigami et al., 2010). In the present study, primary thyroid tumor cells displayed various degrees of B7-H4 expression, and its expression was observed in 95.3% patients with thyroid cancer. These results indicate that the majority of patients with thyroid cancer express B7-H4 and that it may be a useful diagnostic marker for patients with thyroid cancer.

In this study, we showed that B7-H4 expression in human thyroid cancer tissues was significantly correlated with patient’s TNM stage and extrathyroidal extension. Although no significant relationship was detected in the statistical analysis, thyroid cancer patients with high B7-H4 expression tended to display the presence of lymph node metastasis compared with those with low B7-H4 expression. Our findings indicated a close relationship between B7-H4 expression and tumor progression in thyroid cancer. Furthermore, patients with high B7-H4 expression had a poorer prognosis compared with those with low B7-H4 expression in human thyroid cancer. Our studies support the utility of B7-H4 as prognostic biomarkers in thyroid cancer patients undergoing cystectomy.

In conclusion, our results demonstrate that B7-H4 expression is involved in thyroid cancer progression and tumor avoidance of immunosurveillance and could be a useful prognostic indicator for human thyroid cancer. Future studies on the biological behavior of thyroid cancer cells expressing B7-H4 may lead to a new immunotherapy blocking its signaling pathway in patients with thyroid cancer.

Acknowledgements

This work was supported by grants from the Key Fund of Shanghai Municipal Health Bureau (20124015). We are grateful to all staffs of department of general surgery in Xinhua hospital for cooperating with us in the sample collection. The authors have no direct or indirect
commercial financial incentive associated with publishing the article.

References


